Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Original Article

Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer

Authors: Songnan Qi, Mo Huang, Huan Teng, Yudong Lu, Min Jiang, Lin Wang, Jinfang Shi, Qing Ma, Guohao Gu, Yinqiang Xin, Hongwei Ma

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Cancer-associated autoantibodies show promise as sensitive biomarkers for the early detection of cancer. To test the immunogenicity of chromogranin A (ChgA) as a B cell autoantigen and to assess the potential applications of ChgA autoantibodies as novel biomarkers for the diagnosis of non-small cell lung cancer (NSCLC), we developed a high-content peptide microarray using ChgA peptides. Autoantibody profiling was carried out using sera from 168 individuals with NSCLC and 97 healthy controls. We present evidence for the occurrence of autoantibodies to ChgA peptides in patient sera and identified five highly responsive peptides in the NSCLC group using significance analysis of microarray (SAM). Receiver operating characteristic analyses showed that ChgA autoantibodies are valuable in the predictive diagnosis of NSCLC, suggesting that serum autoantibodies to ChgA-derived peptides are promising novel markers of NSCLC. Moreover, the high-content peptide microarray antibody profiling reported in this work provides a powerful tool to visualize the overall B cell response to ChgA peptides and should enable the rapid development of in-depth research into ChgA.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014.
2.
Berendsen HH, De Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. Journal of Clinical Oncology. 1989;7(11):1614–20.CrossRefPubMed
3.
Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. Journal of Clinical Oncology. 1989;7(10):1398–406.CrossRefPubMed
4.
Howe M, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS. Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46(2):195–201.CrossRefPubMed
5.
Chiari M, Cretich M, Corti A, Damin F, Pirri G, Longhi R. Peptide microarrays for the characterization of antigenic regions of human chromogranin A. Proteomics. 2005;5(14):3600–3.CrossRefPubMed
6.
O'connor D, Frigon R. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. Journal of Biological Chemistry. 1984;259(5):3237–47.PubMed
7.
Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. The New England Journal of Medicine. 1989;320(7):444–7.CrossRefPubMed
8.
Nisman B, Heching N, Biran H, Barak V, Peretz T. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumor Biology. 2006;27(1):8–16.CrossRefPubMed
9.
Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A—biological function and clinical utility in neuroendocrine tumor disease. Annals of Surgical Oncology. 2010;17(9):2427–43.CrossRefPubMed
10.
Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nature Immunology. 2010;11(3):225–31.CrossRefPubMedPubMedCentral
11.
Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, et al. Chromogranin A is a T cell antigen in human type 1 diabetes. Journal of Autoimmunity. 2014;50:38–41.CrossRefPubMed
12.
Tan HT, Low J, Lim SG, Chung M. Serum autoantibodies as biomarkers for early cancer detection. FEBS Journal. 2009;276(23):6880–904.CrossRefPubMed
13.
Leidinger P, Keller A, Ludwig N, Rheinheimer S, Hamacher J, Huwer H, et al. Toward an early diagnosis of lung cancer: an autoantibody signature for squamous cell lung carcinoma. International Journal of Cancer. 2008;123(7):1631–6.CrossRefPubMed
14.
Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clinical Cancer Research. 2010;16(14):3760–8.PubMed
15.
Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biology. 2012;33(5):1319–26.CrossRefPubMed
16.
Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Journal of proteome research. 2008;7(4):1388–94.CrossRefPubMed
17.
Ma H, Wu Y, Yang X, Liu X, He J, Fu L, et al. Integrated poly (dimethysiloxane) with an intrinsic nonfouling property approaching “absolute” zero background in immunoassays. Analytical chemistry. 2010;82(15):6338–42.CrossRefPubMed
18.
Larsen J, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2(2):1–7.
19.
Hecker M, Lorenz P, Steinbeck F, Hong L, Riemekasten G, Li Y, et al. Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. Autoimmunity reviews. 2012;11(3):180–90.CrossRefPubMed
20.
Corti A. Chromogranin A, and the tumor microenvironment. Cellular and molecular neurobiology. 2010;30(8):1163–70.CrossRefPubMed
21.
Lu L, Wang YN, Li MC, Wang HB, Pu LJ, Niu WQ, et al. Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease. European Heart Journal. 2012;33(18):2297–306.CrossRefPubMed
22.
Nikoopour E, Cheung R, Bellemore S, Krougly O, Lee‐Chan E, Stridsberg M, et al. Vasostatin‐1 antigenic epitope mapping for induction of cellular and humoral immune responses to chromogranin A autoantigen in NOD mice. European journal of immunology. 2014;44(4):1170–80.CrossRefPubMed
Metadata
Title
Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer
Authors
Songnan Qi
Mo Huang
Huan Teng
Yudong Lu
Min Jiang
Lin Wang
Jinfang Shi
Qing Ma
Guohao Gu
Yinqiang Xin
Hongwei Ma
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3794-3

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Research Article

Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma

Research Article

Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression

Erratum

Erratum to: Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma

Research Article

Prognostic significance of the tumour-adjacent tissue in head and neck cancers

Review

Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment

Research Article

Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits